… recommend the use of neurohormonal blocking agents in HF patients [2, 3] … VALsartan In
Acute myocardial iNfarcTion (VALIANT) trial that evaluated the effects of captopril and valsartan…

… used to stain 4-µm-thick paraffin sections of infarct core samples. Picrosirius red staining of
the infarct core and the remote zone was used … of post-myocardial infarction and heart failure …

… of the patients to either ramipril or sacubitril/valsartan our … and sacubitril valsartan in relation
to use of MRA Patients were … these patients were as expected at higher risk than patients not …

… and captopril group as compared to captopril and valsartan … patients with LVEF ≤40%
reduces the risk of cardiovascular events. HF guidelines recommend the use of ARBs in patients …

… There is a lack of studies comparing the risk of cardio-cerebrovascular disease between …
infarction (MI), heart failure (HF), and cerebrovascular disease with the use of valsartan, losartan…

… (LV) remodeling post myocardial infarction (post-MI) [ 1 , 2 ], … (ARB) in the treatment of
heart failure with reduced ejection … Therefore, the application of Sac/Val in patients with AAMI …

… the mainstays of treatment for patients with LVSD after myocardial infarction (46). Whether
sacubitril and valsartan can be used early in patients with heart failure after acute myocardial …

… , open label sacubitril/valsartan use was anticipated to confound the recurrent event … use of
open label sacubitril/valsartan (<10%) in patients developing symptomatic heart failure during …

… with risk of cardiovascular death or incident heart failure. … , and β-blockers, also attenuate
post–myocardial infarction (MI) LV … Use of other cardiovascular medications was also similar …

… combination with sodium-glucose co-transporter 2 inhibitors or in post-myocardial infarction
HF. … , a wider and earlier use of S/V in the management of HF patients should be considered. …